Pharma BD Deal Intelligence

Merck & Co. Inc. / Inspire Pharmaceuticals, Inc.

2011 · Acquisition/Merger · $430M · Complete

Announcement Sentiment

Strongly positive

Merck acquired Inspire Pharmaceuticals for $5.00/share cash, total ~$430M, to expand its ophthalmic franchise. Inspire products included AzaSite (azithromycin ophthalmic) and US co-promotion rights to Restasis. Closed May 2011.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Dilutive

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Apr 04, 2011
Closed May 16, 2011
Deal value $430M
Deal type Acquisition/Merger
Therapeutic area Ophthalmic disorders (dry eye, conjunctivitis)
Indications Ophthalmic disorders (dry eye, conjunctivitis)
Key assets AzaSite, Restasis (US co-promotion), Elestat, ophthalmic pipeline
Mechanism Topical ophthalmic anti-inflammatories / antibiotics

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals